Literature DB >> 29663159

Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study.

Hossein Maghsoudi1, Jamal Hallajzadeh2, Mozhghan Rezaeipour3.   

Abstract

Osteoarthritis (OA) is a chronic degenerative joint disease with inflammatory component. It is associated with progressive histological alterations and disabling symptoms. Today, drugs such as glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSIADs) are commonly employed for treatment of osteoarthritis, but have serious and life-threatening side effects. The aim of the current study is to evaluate the effects of escin on cyclooxygenase-2 (COX-2, isoform), inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-α), and nitric oxide (NO) (1), as well as prostaglandin E2 (PGE2) on inflammatory cells, similar osteoarthritis in synoviocytes, and monocytes/macrophages, and to compare it with dexamethasone (DEX) and ibuprofen (IBP). Synovial cells were isolated from synovial membrane of the radiocarpal joint cartilage of an 8-month-old Holstein cow. THP-1 cells were prepared from Pasteur Institute of Iran. Cells were cultivated and exposed to lipopolysaccharide (LPS) stimulation without, or in the presence of, DEX, IBP, or escin. The gene expressions of IL-1β, TNF-α, IL-18, COX-2, and iNOS were evaluated by real-time PCR. Concentrations of NO and PGE2 were measured by ELISA methods. Our cells secreted an increased amounts of IL-1β, TNF-α, IL-18, COX-2, iNOS, NO, and PGE2 in response to LPS stimulation in all conditions. Escin can quench the gene expression of COX-2, iNOS, IL-1β, IL-18, and TNF-α in synoviocyte cells and production of NO and PGE2 in monocyte/macrophage cells alike DEX and IBP. We can use from escin for the treatment of osteoarthritis as an anti-inflammatory agent in the latter but further studies to support the results from such a model are needed.

Entities:  

Keywords:  DEX; Escin; IBP; Monocytes/macrophages; Osteoarthritis; Synoviocyte

Mesh:

Substances:

Year:  2018        PMID: 29663159     DOI: 10.1007/s10067-018-4097-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

2.  Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways.

Authors:  Mi-La Cho; Young Ok Jung; Young-Mi Moon; So-Youn Min; Chong-Hyeon Yoon; Sang-Heon Lee; Sung-Hwan Park; Chul-Soo Cho; Dae-Myung Jue; Ho-Youn Kim
Journal:  Immunol Lett       Date:  2005-11-16       Impact factor: 3.685

3.  Effects of beta-Aescin on the expression of nuclear factor-kappaB and tumor necrosis factor-alpha after traumatic brain injury in rats.

Authors:  Guo-min Xiao; Jing Wei
Journal:  J Zhejiang Univ Sci B       Date:  2005-01       Impact factor: 3.066

4.  Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.

Authors:  Angel Lanas; Guillermo Garcia-Tell; Beatriz Armada; Angel Oteo-Alvaro
Journal:  BMC Med       Date:  2011-04-14       Impact factor: 8.775

Review 5.  Cyclooxygenase in biology and disease.

Authors:  R N Dubois; S B Abramson; L Crofford; R A Gupta; L S Simon; L B Van De Putte; P E Lipsky
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

6.  Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro.

Authors:  Wenyu Xin; Leiming Zhang; Fang Sun; Na Jiang; Huaying Fan; Tian Wang; Zhen Li; Jie He; Fenghua Fu
Journal:  Phytomedicine       Date:  2010-09-18       Impact factor: 5.340

7.  Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation.

Authors:  Hiroyuki Futani; Akira Okayama; Kiyoshi Matsui; Shinichiro Kashiwamura; Takashi Sasaki; Toshikazu Hada; Kenji Nakanishi; Hiroomi Tateishi; Soji Maruo; Haruki Okamura
Journal:  J Immunother       Date:  2002 Mar-Apr       Impact factor: 4.456

8.  Association of occupational activity with radiographic knee osteoarthritis and lumbar spondylosis in elderly patients of population-based cohorts: a large-scale population-based study.

Authors:  Shigeyuki Muraki; Toru Akune; Hiroyuki Oka; Akihiko Mabuchi; Yoshio En-Yo; Munehito Yoshida; Akihiko Saika; Kozo Nakamura; Hiroshi Kawaguchi; Noriko Yoshimura
Journal:  Arthritis Rheum       Date:  2009-06-15

9.  The novel role of β-aescin in attenuating CCl4-induced hepatotoxicity in rats.

Authors:  Harsimran Singh; Shabir Sidhu; Kanwaljit Chopra; M U Khan
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

10.  Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF-κB signaling pathway, but not the COX/PGF2α signaling pathway.

Authors:  Hongsheng Wang; Leiming Zhang; Na Jiang; Zhenhua Wang; Yating Chong; Fenghua Fu
Journal:  Exp Ther Med       Date:  2013-05-22       Impact factor: 2.447

View more
  2 in total

1.  Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2.

Authors:  Mohamed Raafat; Amr A Kamel; Alaa H Shehata; Al-Shaimaa F Ahmed; Asmaa M A Bayoumi; Rabab A Moussa; Mohammed A S Abourehab; Mahmoud El-Daly
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-22

2.  In vitro activity of anti-rheumatic drugs on release of pro-inflammatory cytokines from oral cells in interaction with microorganisms.

Authors:  Alexandra Stähli; Carina Scherler; Graziano Zappalà; Anton Sculean; Sigrun Eick
Journal:  Front Oral Health       Date:  2022-09-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.